RBC maintains Kos at outperform

RBC Capital Markets analyst Ken Trbovich maintained Kos Pharmaceuticals, Inc. at outperform, average risk, with a lowered price target of $55 from $60. For the quarter, Kos reduced top line guidance, while its earnings guidance remained basically unchanged. The analyst believes the outlook for 2007 is positive with the termination of Takeda co-promotion and completion of channel inventory reduction. Shares of the Cranbury, N.J.-based pharmaceutical company were up 54 cents, or 1.29%, at $42.46, on volume of 906,850 shares versus the three-month running average of 600,058 shares. (Nasdaq: KOSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.